Ovarian PRP / PRGF
Ovarian PRP / PRGF therapy is a modern regenerative medicine approach used in certain cases of female infertility. The method is based on the use of plasma derived from the patient’s own body, with the aim of supporting tissue healing and regeneration.
In the context of assisted reproduction, their application to the ovaries is being investigated as a possible way to support ovarian function in selected cases.
What are ovarian PRP and PRGF
PRP (Platelet Rich Plasma) is blood plasma rich in platelets, derived from the patient’s own blood after special laboratory processing. Platelets contain growth factors and bioactive proteins that participate in tissue healing and regeneration.
In the case of PRP application to the ovaries, the processed plasma is injected into the ovaries with the aim of stimulating biological mechanisms related to the function of ovarian tissue.
PRGF (Plasma Rich in Growth Factors) is an advanced form of PRP therapy. This method involves specialized plasma processing aimed at achieving a higher concentration of growth factors, which are believed to contribute to the therapy’s regenerative action.
How PRP / PRGF therapy may help
Ovarian PRP / PRGF therapy is being investigated as a method that may support ovarian function in selected cases of women with diminished ovarian reserve or reduced response to ovarian stimulation.
In some cases, changes may be observed after treatment in parameters related to ovarian function.
Possible improvement in hormonal markers
After PRP / PRGF therapy, changes may be observed in hormonal markers related to ovarian function, such as FSH, LH, or AMH. These hormonal parameters are evaluated as part of medical follow-up after treatment.
Increase in the number of follicles
In some women, an increase in the number of follicles developing during the cycle has been observed, which may affect ovarian response in future assisted reproduction attempts.
Support for response to IVF treatment
In some cases, the application of this therapy may contribute to improved ovarian response in in vitro fertilization cycles, increasing the number of oocytes retrieved or embryos obtained.
Possibility of natural conception
In some cases, the return of ovulation or improvement in ovarian function after treatment has been reported, which may create the conditions for natural conception.
In which cases may PRP / PRGF therapy be recommended?
Diminished ovarian reserve
The therapy may be considered in women with low ovarian reserve, that is, when the number of available oocytes is reduced. Evaluation is usually based on hormonal markers such as AMH and ultrasound assessment of the number of follicles.
Premature ovarian insufficiency
In women with premature ovarian insufficiency, where ovarian function declines before the age of natural menopause, PRP / PRGF therapy is being investigated as a possible method to support ovarian activity.
Low response to ovarian stimulation (poor responders)
The therapy may also be proposed for women who show a low response to pharmacological ovarian stimulation during IVF cycles, meaning that a small number of oocytes is produced.
Perimenopausal women
In certain cases involving perimenopausal women, the therapy may be considered as part of exploring options to maintain or support ovarian function.
How PRP / PRGF therapy is performed (H2)
Blood collection and plasma preparation
The procedure begins with the collection of a small amount of blood from the patient. The sample is transferred to the laboratory, where it undergoes special centrifugation processing in order to separate the platelet-rich plasma from the other blood components.
Laboratory processing
After separation, the plasma containing a high concentration of platelets and growth factors is collected and prepared for use. In the case of the PRGF technique, additional processing is applied to achieve a higher concentration of growth factors.
Injection of PRP / PRGF into the ovaries
The processed plasma is injected into the ovaries with the aid of transvaginal ultrasound, using a technique similar to egg retrieval. The procedure is usually performed under light anesthesia or sedation and takes only a few minutes. After completion, the patient can usually return home the same day.
After treatment and follow-up
After the therapy is administered, a period of medical follow-up follows with the aim of evaluating ovarian response. This follow-up may include hormonal blood tests and ultrasound examination of the ovaries.
Usually, markers related to ovarian function are assessed, such as FSH, LH, AMH, and estradiol levels. At the same time, ultrasound examination may be used to evaluate the presence and number of follicles.
The assessment of response to treatment is carried out gradually over the following months. In some cases, changes in hormonal markers or ovarian activity may be observed within a few months after the therapy is administered.
Possible side effects and contraindications
Ovarian PRP / PRGF therapy is generally considered well tolerated, as biological material derived from the patient’s own blood is used. For this reason, the risk of allergic reactions or rejection is particularly low.
The most common adverse effects that may occur are usually mild and temporary, such as mild pain or discomfort in the injection area.
Although complications are rare, the therapy is not indicated in all cases. For example, it may not be recommended for patients with severe hematological disorders, active infections, a history of malignancy, or in cases where specific medications affecting platelet function are being taken.
For this reason, a detailed medical evaluation is always performed before the therapy is administered, in order to assess whether the method is appropriate for each patient.
Frequently Asked Questions (FAQ)
The possible results of the therapy do not appear immediately. Ovarian response is usually evaluated within the following 1 to 3 months after the therapy is administered. During this period, hormonal markers and ultrasound findings related to ovarian function are monitored.
The duration of the possible effect of the therapy may vary from woman to woman. In some cases, results may be observed for several months, during which an attempt at natural conception or an IVF cycle may be carried out.
In some cases, repeating the therapy may be considered, especially when a positive response has been observed after the first application. The decision to repeat it is always made after medical evaluation and monitoring of ovarian response.
Yes, in some cases the therapy is administered before an IVF cycle with the aim of potentially improving ovarian response to stimulation. The exact treatment plan depends on each patient’s characteristics and medical history.
Get a second opinion! Schedule an appointment
